Market Research Report

Global Wearable Continuous Glucose Monitoring Devices Market Insights, Size, and Forecast By End User (Hospitals, Homecare Settings, Ambulatory Surgical Centers, Others), By Indication (Type 1 Diabetes, Type 2 Diabetes, Prediabetes/Lifestyle Monitoring), By Device Type (Implantable CGM Devices, Non-Implantable CGM Devices), By Age Group (Pediatric, Adult, Geriatric), By Component (Sensors, Transmitters, Receivers/Display Devices, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035

Report ID:45527
Published Date:Mar 2026
No. of Pages:240
Base Year for Estimate:2025
Format:
Customize Report

Key Market Insights

Global Wearable Continuous Glucose Monitoring Devices Market is projected to grow from USD 14.8 Billion in 2025 to USD 52.5 Billion by 2035, reflecting a compound annual growth rate of 14.2% from 2026 through 2035. This significant expansion underscores the critical role of wearable CGM devices in modern diabetes management, offering real-time glucose insights and improving patient outcomes. The market is broadly segmented by Component, Device Type, Indication, Age Group, and End User, with the Sensors segment currently dominating due to their essential role in data collection. Key market drivers include the escalating global prevalence of diabetes, increased awareness and adoption of proactive health management technologies, and a growing preference for minimally invasive or non-invasive monitoring solutions. Technological advancements, such as enhanced accuracy, extended wear times, and integration with other smart devices, further fuel market growth. However, market growth is tempered by factors such as high device costs, limited reimbursement policies in some regions, and data privacy concerns associated with health monitoring devices. Opportunities lie in expanding into emerging markets, developing more affordable and accessible solutions, and leveraging AI and machine learning for predictive analytics and personalized care.

Global Wearable Continuous Glucose Monitoring Devices Market Value (USD Billion) Analysis, 2025-2035

maklogo
14.2%
CAGR from
2025 - 2035
Source:
www.makdatainsights.com

North America maintains its position as the dominant region in the wearable CGM devices market. This leadership is attributable to a well-established healthcare infrastructure, high awareness among both patients and healthcare professionals, favorable reimbursement policies, and the early adoption of advanced medical technologies. The presence of key market players and a robust research and development ecosystem also contribute significantly to North America’s stronghold. Conversely, Asia Pacific is anticipated to emerge as the fastest growing region over the forecast period. This accelerated growth is driven by a large and rapidly expanding diabetic population, increasing healthcare expenditure, improving economic conditions, and a rising awareness regarding diabetes management in countries like China and India. Government initiatives to improve healthcare access and a growing demand for advanced medical technologies are also key contributors to the region's rapid ascent. The market's competitive landscape is characterized by both established pharmaceutical companies and specialized medical device manufacturers.

Key players such as Afon Technology Ltd, Tandem Diabetes Care Inc., Medtronic plc, Dexcom Inc., A. Menarini Diagnostics Srl, Byram Healthcare Centers Inc., Murata Manufacturing Co. Ltd., Senseonics Holdings Inc., Ascensia Diabetes Care Holdings AG, and F. Hoffmann‑La Roche Ltd are actively engaged in strategic initiatives to bolster their market presence. These strategies include continuous innovation in sensor technology, expanding product portfolios to cater to diverse patient needs, strategic collaborations and partnerships to enhance market reach, and significant investments in research and development to introduce next-generation devices. Furthermore, companies are focusing on improving device accuracy, user comfort, and data integration capabilities to provide more comprehensive and user-friendly solutions. The emphasis on real-time data accessibility and integration with digital health platforms is a major trend, empowering patients with better self-management tools and enabling healthcare providers to offer more personalized care, ultimately driving the market toward a more integrated and proactive approach to diabetes management.

Quick Stats

  • Market Size (2025):

    USD 14.8 Billion
  • Projected Market Size (2035):

    USD 52.5 Billion
  • Leading Segment:

    Sensors (55.8% Share)
  • Dominant Region (2025):

    North America (45.2% Share)
  • CAGR (2026-2035):

    14.2%

What are the Key Drivers Shaping the Global Wearable Continuous Glucose Monitoring Devices Market

Rising Prevalence of Diabetes and Chronic Diseases Globally

The increasing global burden of diabetes and various chronic conditions acts as a primary catalyst for the wearable continuous glucose monitoring devices market. As more individuals worldwide are diagnosed with type 1 diabetes type 2 diabetes gestational diabetes and other chronic diseases that impact blood glucose regulation the demand for effective self management tools intensifies. These conditions necessitate constant vigilance over blood sugar levels to prevent acute complications and long term damage. Traditional fingerstick methods are often painful inconvenient and provide only snapshot readings. Wearable CGM devices offer a non invasive continuous and real time solution enabling patients and healthcare providers to track glucose trends understand dietary and activity impacts and make informed decisions for better disease management and improved quality of life. This rising prevalence inherently expands the user base for these innovative monitoring technologies.

Advancements in Sensor Technology and Miniaturization

Innovations in sensor technology and miniaturization are a significant market driver. Advanced electrochemical and optical sensors, now significantly smaller, enhance accuracy and reduce the footprint of wearable CGM devices. This allows for less intrusive and more comfortable designs, improving user adoption and adherence. Miniaturization also facilitates integration into various form factors like patches, watches, and smart rings, expanding the devices appeal beyond traditional users. Enhanced power efficiency, longer battery life, and improved data transmission capabilities further contribute to the practicality and convenience of these compact devices. These technological strides directly address key user demands for discretion, comfort, and extended wear, propelling market growth.

Increasing Demand for Real-time Health Monitoring and Personalized Healthcare

The escalating consumer desire for immediate health insights and tailored medical interventions fuels the growth of wearable continuous glucose monitoring devices. Individuals increasingly seek proactive management of their health, moving beyond reactive care. This surge in demand stems from a heightened awareness of preventable conditions and a preference for personalized wellness strategies. Real time glucose data empowers users to make informed daily decisions about diet, exercise, and medication, optimizing their metabolic control. Healthcare providers also benefit by accessing continuous patient data, enabling more precise diagnoses and individualized treatment plans. The convergence of technological advancement and consumer driven health consciousness directly propels the adoption of these innovative monitoring solutions across the globe.

Global Wearable Continuous Glucose Monitoring Devices Market Restraints

High Cost and Reimbursement Challenges Limit Adoption

High costs significantly hinder the widespread adoption of wearable continuous glucose monitoring devices. The initial purchase price of these advanced sensors and accompanying hardware can be prohibitive for many individuals, particularly those in lower socioeconomic brackets or without robust health insurance. Beyond the upfront expense, the ongoing need for replacement sensors, which often have a limited lifespan, creates a recurring financial burden.

Reimbursement challenges further exacerbate this issue. Insurance coverage for these devices varies considerably across different plans and regions. Some policies may only cover devices for individuals with specific medical conditions or those meeting strict criteria, leaving a substantial portion of the diabetic population without financial assistance. The complexity and inconsistency of reimbursement policies make it difficult for patients to access these beneficial technologies, ultimately restricting market penetration and growth despite the clear health advantages they offer.

Privacy Concerns and Data Security Risks Hinder User Trust

Privacy concerns and data security risks significantly impede user trust in the global wearable continuous glucose monitoring devices market. Individuals are hesitant to adopt these devices due to anxieties surrounding the collection, storage, and potential misuse of highly sensitive personal health information. The continuous nature of glucose monitoring generates a vast amount of intimate physiological data, which, if compromised, could lead to discrimination, exploitation, or unauthorized access to private health profiles. Worries about data breaches, hacking, and the potential for this information to be shared with third parties without explicit consent deter prospective users. This lack of confidence in data protection measures prevents widespread acceptance and slows market expansion. Ensuring robust security protocols and transparent data handling practices is crucial to building the necessary trust for market growth.

Global Wearable Continuous Glucose Monitoring Devices Market Opportunities

Expanding Wearable CGM Adoption into Non-Diabetic Health & Wellness for Proactive Metabolic Management

This opportunity centers on significantly expanding the user base for wearable Continuous Glucose Monitoring devices beyond traditional diabetic patients. It targets the vast segment of non-diabetic individuals keen on proactive health and wellness. By providing real time glucose insights, CGMs empower users to understand their unique metabolic responses to food, exercise, and stress. This personalized data enables them to optimize dietary choices, fine tune workout routines, and manage lifestyle factors to prevent the onset of metabolic dysfunction like pre diabetes or type 2 diabetes. Furthermore, it supports goals such as weight management, enhanced athletic performance, improved energy levels, and better sleep quality. The focus shifts from disease management to optimizing peak human performance and long term metabolic health, appealing to health conscious consumers seeking data driven self improvement. This expansion represents a substantial untapped market, facilitating early intervention and truly personalized nutrition strategies.

Leveraging AI and Telehealth Integration to Personalize Metabolic Insights from Wearable CGM Devices

The convergence of AI and telehealth offers a profound opportunity to revolutionize metabolic health management through wearable Continuous Glucose Monitoring CGM devices. By applying sophisticated artificial intelligence algorithms to real time glucose data, individuals can receive highly personalized insights into their body's unique responses to diet, exercise, and lifestyle choices. This transcends mere data, providing actionable recommendations specifically tailored to prevent metabolic dysfunction or optimize existing conditions. Telehealth platforms then facilitate seamless delivery of these bespoke insights, enabling virtual consultations, remote coaching, and proactive intervention by healthcare professionals. This integration fosters a truly patient centric approach, empowering users to make informed daily decisions and significantly improving long term health outcomes. The global demand for such intelligent, accessible metabolic personalization is immense, especially in digitally embracing regions like Asia Pacific, promising enhanced engagement and more effective preventative care.

Global Wearable Continuous Glucose Monitoring Devices Market Segmentation Analysis

Key Market Segments

By Component

  • Sensors
  • Transmitters
  • Receivers/Display Devices
  • Others

By Device Type

  • Implantable CGM Devices
  • Non-Implantable CGM Devices

By Indication

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Prediabetes/Lifestyle Monitoring

By Age Group

  • Pediatric
  • Adult
  • Geriatric

By End User

  • Hospitals
  • Homecare Settings
  • Ambulatory Surgical Centers
  • Others

Segment Share By Component

Share, By Component, 2025 (%)

  • Sensors
  • Transmitters
  • Receivers/Display Devices
  • Others
maklogo
$14.8BGlobal Market Size, 2025
Source:
www.makdatainsights.com

Why is the Sensors component dominating the Global Wearable Continuous Glucose Monitoring Devices Market?

The Sensors component holds the largest share due to its critical role as the primary interface for glucose detection. These disposable components require regular replacement, driving continuous demand. Technological advancements in sensor accuracy, miniaturization, and extended wear time further contribute to their market prominence, forming the indispensable core of every CGM system that gathers real time data.

How do different Indications influence the demand for wearable continuous glucose monitoring devices?

Type 1 diabetes patients represent a significant driver, as continuous glucose monitoring is often a standard of care for their intensive insulin management. However, the market is increasingly expanding into Type 2 diabetes and even prediabetes or lifestyle monitoring, as awareness grows regarding the benefits of personalized glucose insights for proactive health management and preventing disease progression.

Which End User segments are experiencing significant growth in the adoption of wearable continuous glucose monitoring devices?

While hospitals are key initial points of care, homecare settings are witnessing substantial growth. This trend reflects the shift towards patient empowerment and remote monitoring, allowing individuals to manage their condition more effectively in their daily lives. The convenience and real time data provided by wearable CGMs make them ideal for self management outside traditional clinical environments.

Global Wearable Continuous Glucose Monitoring Devices Market Regulatory and Policy Environment Analysis

The global wearable continuous glucose monitoring market navigates a diverse and stringent regulatory landscape. Regulatory bodies such as the FDA in the United States, EMA in Europe, PMDA in Japan, and NMPA in China classify these devices primarily as Class II or III medical devices, demanding rigorous pre-market approval processes. These involve extensive clinical trials demonstrating accuracy, safety, and efficacy for both professional and personal use. Data privacy regulations, including GDPR and HIPAA, significantly influence device design and data management, given the sensitive nature of health information. Reimbursement policies vary substantially across countries, heavily impacting market access and adoption rates. Many national health systems are progressively recognizing CGM benefits, leading to expanded coverage. Post-market surveillance and reporting requirements ensure ongoing device safety. Furthermore, policies regarding device interoperability with digital health platforms and the integration of artificial intelligence are rapidly developing, shaping future innovation and market dynamics. Harmonization efforts, while ongoing, present challenges due to differing national standards and ethical considerations.

Which Emerging Technologies Are Driving New Trends in the Market?

The global wearable continuous glucose monitoring devices market thrives on continuous innovation. Emerging technologies prioritize user comfort and discretion through significant miniaturization, enabling more discreet form factors and extended wear times. Non invasive glucose sensing methods, including optical and sweat based solutions, are on the horizon, promising a paradigm shift in accessibility and user experience. Artificial intelligence and machine learning algorithms are central to enhancing data accuracy, delivering predictive insights, and personalizing diabetes management strategies. Seamless integration with smartwatches and broader connected health ecosystems is expanding, facilitating real time data flow and remote monitoring capabilities. Further advancements involve multi analyte sensors that provide a more comprehensive metabolic profile, alongside sophisticated closed loop systems intelligently managing insulin delivery. These innovations aim to dramatically improve life quality for individuals with diabetes, offering precise, convenient, and proactive health management.

Global Wearable Continuous Glucose Monitoring Devices Market Regional Analysis

Global Wearable Continuous Glucose Monitoring Devices Market

Trends, by Region

Largest Market
Fastest Growing Market
maklogo
45.2%

North America Market
Revenue Share, 2025

Source:
www.makdatainsights.com

Dominant Region

North America · 45.2% share

North America dominates the Global Wearable Continuous Glucose Monitoring Devices Market with a significant 45.2% market share. This strong position is driven by several key factors. High prevalence of diabetes and prediabetes in the region fuels the demand for advanced monitoring solutions. Furthermore, early adoption of innovative medical technologies, robust healthcare infrastructure, and favorable reimbursement policies contribute significantly to market expansion. The presence of major industry players and ongoing research and development initiatives also bolster North America's leadership. Growing awareness among healthcare professionals and patients regarding the benefits of continuous glucose monitoring further propels its widespread acceptance and adoption across the United States and Canada.

Fastest Growing Region

Asia Pacific · 12.8% CAGR

Asia Pacific is poised to be the fastest growing region in the Global Wearable Continuous Glucose Monitoring Devices Market with an impressive CAGR of 12.8% during the forecast period of 2026 to 2035. This accelerated growth is primarily driven by the increasing prevalence of diabetes across countries like India and China. A rapidly aging population combined with improving healthcare infrastructure and rising disposable incomes further fuels this expansion. Enhanced awareness about diabetes management and the growing adoption of technologically advanced wearable devices also contribute significantly. Government initiatives promoting early diagnosis and better disease management are creating a favorable environment for market penetration and sustained growth in the region.

Impact of Geopolitical and Macroeconomic Factors

Geopolitical stability and trade relations heavily influence the wearable CGM market. Supply chain disruptions, often stemming from geopolitical tensions or natural disasters, can impact device component availability and raise production costs. Moreover, regulatory environments vary across nations; market access for these devices is contingent on navigating diverse approval processes, which are occasionally politicized. International cooperation on healthcare standards and data privacy is crucial, as is intellectual property protection, particularly for emerging technologies. Geopolitical shifts can also influence healthcare investment priorities and consumer confidence in medical technology.

Macroeconomic factors significantly shape market dynamics. Disposable income levels directly correlate with consumer adoption rates, as these devices represent a considerable discretionary healthcare expense. Inflationary pressures can erode purchasing power and increase manufacturing costs, potentially leading to higher device prices. Healthcare expenditure trends, influenced by government policies and insurance coverage expansion, play a vital role in market penetration. Economic growth fosters greater investment in healthcare infrastructure and innovation, supporting market expansion. Exchange rate fluctuations also impact profitability for companies operating across multiple countries.

Recent Developments

  • March 2025

    Dexcom Inc. announced a strategic partnership with a leading digital health platform to integrate its G7 CGM data directly into personalized diabetes management applications. This collaboration aims to provide users with more comprehensive insights and facilitate proactive health interventions through AI-driven analytics.

  • September 2024

    Medtronic plc launched its next-generation integrated CGM system, designed for enhanced accuracy and a longer wear time, reducing the frequency of sensor changes for users. This new product also features improved connectivity with insulin pumps and a user-friendly mobile application.

  • July 2025

    Afon Technology Ltd, a notable innovator in non-invasive CGM technology, secured significant Series B funding, enabling accelerated research and development for their highly anticipated product. This investment positions Afon to further disrupt the market with its unique approach to glucose monitoring.

  • November 2024

    Ascensia Diabetes Care Holdings AG formed a strategic alliance with a major pharmaceutical company to explore the integration of CGM data into drug development and patient support programs. This partnership aims to leverage real-world data for more personalized therapeutic approaches in diabetes management.

Key Players Analysis

Key players like Dexcom Inc. and Abbott Laboratories (not listed but a leader) dominate the continuous glucose monitoring market with advanced sensor technologies driving growth. Medtronic plc and Senseonics Holdings Inc. offer innovative solutions, while strategic initiatives such as partnerships (e.g., A. Menarini Diagnostics Srl) and expanded insurance coverage (Byram Healthcare Centers Inc.) further fuel market expansion. Tandem Diabetes Care Inc. integrates CGM with insulin pumps, enhancing user convenience and driving adoption.

List of Key Companies:

  1. Afon Technology Ltd
  2. Tandem Diabetes Care Inc.
  3. Medtronic plc
  4. Dexcom Inc.
  5. A. Menarini Diagnostics Srl
  6. Byram Healthcare Centers Inc.
  7. Murata Manufacturing Co. Ltd.
  8. Senseonics Holdings Inc.
  9. Ascensia Diabetes Care Holdings AG
  10. F. Hoffmann‑La Roche Ltd
  11. Abbott Laboratories
  12. Know Labs Inc.

Report Scope and Segmentation

Report ComponentDescription
Market Size (2025)USD 14.8 Billion
Forecast Value (2035)USD 52.5 Billion
CAGR (2026-2035)14.2%
Base Year2025
Historical Period2020-2025
Forecast Period2026-2035
Segments Covered
  • By Component:
    • Sensors
    • Transmitters
    • Receivers/Display Devices
    • Others
  • By Device Type:
    • Implantable CGM Devices
    • Non-Implantable CGM Devices
  • By Indication:
    • Type 1 Diabetes
    • Type 2 Diabetes
    • Prediabetes/Lifestyle Monitoring
  • By Age Group:
    • Pediatric
    • Adult
    • Geriatric
  • By End User:
    • Hospitals
    • Homecare Settings
    • Ambulatory Surgical Centers
    • Others
Regional Analysis
  • North America
  • • United States
  • • Canada
  • Europe
  • • Germany
  • • France
  • • United Kingdom
  • • Spain
  • • Italy
  • • Russia
  • • Rest of Europe
  • Asia-Pacific
  • • China
  • • India
  • • Japan
  • • South Korea
  • • New Zealand
  • • Singapore
  • • Vietnam
  • • Indonesia
  • • Rest of Asia-Pacific
  • Latin America
  • • Brazil
  • • Mexico
  • • Rest of Latin America
  • Middle East and Africa
  • • South Africa
  • • Saudi Arabia
  • • UAE
  • • Rest of Middle East and Africa

Table of Contents:

1. Introduction
1.1. Objectives of Research
1.2. Market Definition
1.3. Market Scope
1.4. Research Methodology
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Market Factor Analysis
4.1. Porter's Five Forces Model Analysis
4.1.1. Rivalry among Existing Competitors
4.1.2. Bargaining Power of Buyers
4.1.3. Bargaining Power of Suppliers
4.1.4. Threat of Substitute Products or Services
4.1.5. Threat of New Entrants
4.2. PESTEL Analysis
4.2.1. Political Factors
4.2.2. Economic & Social Factors
4.2.3. Technological Factors
4.2.4. Environmental Factors
4.2.5. Legal Factors
4.3. Supply and Value Chain Assessment
4.4. Regulatory and Policy Environment Review
4.5. Market Investment Attractiveness Index
4.6. Technological Innovation and Advancement Review
4.7. Impact of Geopolitical and Macroeconomic Factors
4.8. Trade Dynamics: Import-Export Assessment (Where Applicable)
5. Global Wearable Continuous Glucose Monitoring Devices Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
5.1. Market Analysis, Insights and Forecast, 2020-2035, By Component
5.1.1. Sensors
5.1.2. Transmitters
5.1.3. Receivers/Display Devices
5.1.4. Others
5.2. Market Analysis, Insights and Forecast, 2020-2035, By Device Type
5.2.1. Implantable CGM Devices
5.2.2. Non-Implantable CGM Devices
5.3. Market Analysis, Insights and Forecast, 2020-2035, By Indication
5.3.1. Type 1 Diabetes
5.3.2. Type 2 Diabetes
5.3.3. Prediabetes/Lifestyle Monitoring
5.4. Market Analysis, Insights and Forecast, 2020-2035, By Age Group
5.4.1. Pediatric
5.4.2. Adult
5.4.3. Geriatric
5.5. Market Analysis, Insights and Forecast, 2020-2035, By End User
5.5.1. Hospitals
5.5.2. Homecare Settings
5.5.3. Ambulatory Surgical Centers
5.5.4. Others
5.6. Market Analysis, Insights and Forecast, 2020-2035, By Region
5.6.1. North America
5.6.2. Europe
5.6.3. Asia-Pacific
5.6.4. Latin America
5.6.5. Middle East and Africa
6. North America Wearable Continuous Glucose Monitoring Devices Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
6.1. Market Analysis, Insights and Forecast, 2020-2035, By Component
6.1.1. Sensors
6.1.2. Transmitters
6.1.3. Receivers/Display Devices
6.1.4. Others
6.2. Market Analysis, Insights and Forecast, 2020-2035, By Device Type
6.2.1. Implantable CGM Devices
6.2.2. Non-Implantable CGM Devices
6.3. Market Analysis, Insights and Forecast, 2020-2035, By Indication
6.3.1. Type 1 Diabetes
6.3.2. Type 2 Diabetes
6.3.3. Prediabetes/Lifestyle Monitoring
6.4. Market Analysis, Insights and Forecast, 2020-2035, By Age Group
6.4.1. Pediatric
6.4.2. Adult
6.4.3. Geriatric
6.5. Market Analysis, Insights and Forecast, 2020-2035, By End User
6.5.1. Hospitals
6.5.2. Homecare Settings
6.5.3. Ambulatory Surgical Centers
6.5.4. Others
6.6. Market Analysis, Insights and Forecast, 2020-2035, By Country
6.6.1. United States
6.6.2. Canada
7. Europe Wearable Continuous Glucose Monitoring Devices Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
7.1. Market Analysis, Insights and Forecast, 2020-2035, By Component
7.1.1. Sensors
7.1.2. Transmitters
7.1.3. Receivers/Display Devices
7.1.4. Others
7.2. Market Analysis, Insights and Forecast, 2020-2035, By Device Type
7.2.1. Implantable CGM Devices
7.2.2. Non-Implantable CGM Devices
7.3. Market Analysis, Insights and Forecast, 2020-2035, By Indication
7.3.1. Type 1 Diabetes
7.3.2. Type 2 Diabetes
7.3.3. Prediabetes/Lifestyle Monitoring
7.4. Market Analysis, Insights and Forecast, 2020-2035, By Age Group
7.4.1. Pediatric
7.4.2. Adult
7.4.3. Geriatric
7.5. Market Analysis, Insights and Forecast, 2020-2035, By End User
7.5.1. Hospitals
7.5.2. Homecare Settings
7.5.3. Ambulatory Surgical Centers
7.5.4. Others
7.6. Market Analysis, Insights and Forecast, 2020-2035, By Country
7.6.1. Germany
7.6.2. France
7.6.3. United Kingdom
7.6.4. Spain
7.6.5. Italy
7.6.6. Russia
7.6.7. Rest of Europe
8. Asia-Pacific Wearable Continuous Glucose Monitoring Devices Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
8.1. Market Analysis, Insights and Forecast, 2020-2035, By Component
8.1.1. Sensors
8.1.2. Transmitters
8.1.3. Receivers/Display Devices
8.1.4. Others
8.2. Market Analysis, Insights and Forecast, 2020-2035, By Device Type
8.2.1. Implantable CGM Devices
8.2.2. Non-Implantable CGM Devices
8.3. Market Analysis, Insights and Forecast, 2020-2035, By Indication
8.3.1. Type 1 Diabetes
8.3.2. Type 2 Diabetes
8.3.3. Prediabetes/Lifestyle Monitoring
8.4. Market Analysis, Insights and Forecast, 2020-2035, By Age Group
8.4.1. Pediatric
8.4.2. Adult
8.4.3. Geriatric
8.5. Market Analysis, Insights and Forecast, 2020-2035, By End User
8.5.1. Hospitals
8.5.2. Homecare Settings
8.5.3. Ambulatory Surgical Centers
8.5.4. Others
8.6. Market Analysis, Insights and Forecast, 2020-2035, By Country
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. New Zealand
8.6.6. Singapore
8.6.7. Vietnam
8.6.8. Indonesia
8.6.9. Rest of Asia-Pacific
9. Latin America Wearable Continuous Glucose Monitoring Devices Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
9.1. Market Analysis, Insights and Forecast, 2020-2035, By Component
9.1.1. Sensors
9.1.2. Transmitters
9.1.3. Receivers/Display Devices
9.1.4. Others
9.2. Market Analysis, Insights and Forecast, 2020-2035, By Device Type
9.2.1. Implantable CGM Devices
9.2.2. Non-Implantable CGM Devices
9.3. Market Analysis, Insights and Forecast, 2020-2035, By Indication
9.3.1. Type 1 Diabetes
9.3.2. Type 2 Diabetes
9.3.3. Prediabetes/Lifestyle Monitoring
9.4. Market Analysis, Insights and Forecast, 2020-2035, By Age Group
9.4.1. Pediatric
9.4.2. Adult
9.4.3. Geriatric
9.5. Market Analysis, Insights and Forecast, 2020-2035, By End User
9.5.1. Hospitals
9.5.2. Homecare Settings
9.5.3. Ambulatory Surgical Centers
9.5.4. Others
9.6. Market Analysis, Insights and Forecast, 2020-2035, By Country
9.6.1. Brazil
9.6.2. Mexico
9.6.3. Rest of Latin America
10. Middle East and Africa Wearable Continuous Glucose Monitoring Devices Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
10.1. Market Analysis, Insights and Forecast, 2020-2035, By Component
10.1.1. Sensors
10.1.2. Transmitters
10.1.3. Receivers/Display Devices
10.1.4. Others
10.2. Market Analysis, Insights and Forecast, 2020-2035, By Device Type
10.2.1. Implantable CGM Devices
10.2.2. Non-Implantable CGM Devices
10.3. Market Analysis, Insights and Forecast, 2020-2035, By Indication
10.3.1. Type 1 Diabetes
10.3.2. Type 2 Diabetes
10.3.3. Prediabetes/Lifestyle Monitoring
10.4. Market Analysis, Insights and Forecast, 2020-2035, By Age Group
10.4.1. Pediatric
10.4.2. Adult
10.4.3. Geriatric
10.5. Market Analysis, Insights and Forecast, 2020-2035, By End User
10.5.1. Hospitals
10.5.2. Homecare Settings
10.5.3. Ambulatory Surgical Centers
10.5.4. Others
10.6. Market Analysis, Insights and Forecast, 2020-2035, By Country
10.6.1. South Africa
10.6.2. Saudi Arabia
10.6.3. UAE
10.6.4. Rest of Middle East and Africa
11. Competitive Analysis and Company Profiles
11.1. Market Share of Key Players
11.1.1. Global Company Market Share
11.1.2. Regional/Sub-Regional Company Market Share
11.2. Company Profiles
11.2.1. Afon Technology Ltd
11.2.1.1. Business Overview
11.2.1.2. Products Offering
11.2.1.3. Financial Insights (Based on Availability)
11.2.1.4. Company Market Share Analysis
11.2.1.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.1.6. Strategy
11.2.1.7. SWOT Analysis
11.2.2. Tandem Diabetes Care Inc.
11.2.2.1. Business Overview
11.2.2.2. Products Offering
11.2.2.3. Financial Insights (Based on Availability)
11.2.2.4. Company Market Share Analysis
11.2.2.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.2.6. Strategy
11.2.2.7. SWOT Analysis
11.2.3. Medtronic plc
11.2.3.1. Business Overview
11.2.3.2. Products Offering
11.2.3.3. Financial Insights (Based on Availability)
11.2.3.4. Company Market Share Analysis
11.2.3.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.3.6. Strategy
11.2.3.7. SWOT Analysis
11.2.4. Dexcom Inc.
11.2.4.1. Business Overview
11.2.4.2. Products Offering
11.2.4.3. Financial Insights (Based on Availability)
11.2.4.4. Company Market Share Analysis
11.2.4.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.4.6. Strategy
11.2.4.7. SWOT Analysis
11.2.5. A. Menarini Diagnostics Srl
11.2.5.1. Business Overview
11.2.5.2. Products Offering
11.2.5.3. Financial Insights (Based on Availability)
11.2.5.4. Company Market Share Analysis
11.2.5.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.5.6. Strategy
11.2.5.7. SWOT Analysis
11.2.6. Byram Healthcare Centers Inc.
11.2.6.1. Business Overview
11.2.6.2. Products Offering
11.2.6.3. Financial Insights (Based on Availability)
11.2.6.4. Company Market Share Analysis
11.2.6.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.6.6. Strategy
11.2.6.7. SWOT Analysis
11.2.7. Murata Manufacturing Co. Ltd.
11.2.7.1. Business Overview
11.2.7.2. Products Offering
11.2.7.3. Financial Insights (Based on Availability)
11.2.7.4. Company Market Share Analysis
11.2.7.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.7.6. Strategy
11.2.7.7. SWOT Analysis
11.2.8. Senseonics Holdings Inc.
11.2.8.1. Business Overview
11.2.8.2. Products Offering
11.2.8.3. Financial Insights (Based on Availability)
11.2.8.4. Company Market Share Analysis
11.2.8.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.8.6. Strategy
11.2.8.7. SWOT Analysis
11.2.9. Ascensia Diabetes Care Holdings AG
11.2.9.1. Business Overview
11.2.9.2. Products Offering
11.2.9.3. Financial Insights (Based on Availability)
11.2.9.4. Company Market Share Analysis
11.2.9.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.9.6. Strategy
11.2.9.7. SWOT Analysis
11.2.10. F. Hoffmann‑La Roche Ltd
11.2.10.1. Business Overview
11.2.10.2. Products Offering
11.2.10.3. Financial Insights (Based on Availability)
11.2.10.4. Company Market Share Analysis
11.2.10.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.10.6. Strategy
11.2.10.7. SWOT Analysis
11.2.11. Abbott Laboratories
11.2.11.1. Business Overview
11.2.11.2. Products Offering
11.2.11.3. Financial Insights (Based on Availability)
11.2.11.4. Company Market Share Analysis
11.2.11.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.11.6. Strategy
11.2.11.7. SWOT Analysis
11.2.12. Know Labs Inc.
11.2.12.1. Business Overview
11.2.12.2. Products Offering
11.2.12.3. Financial Insights (Based on Availability)
11.2.12.4. Company Market Share Analysis
11.2.12.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.12.6. Strategy
11.2.12.7. SWOT Analysis

List of Figures

List of Tables

Table 1: Global Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Component, 2020-2035

Table 2: Global Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Device Type, 2020-2035

Table 3: Global Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Indication, 2020-2035

Table 4: Global Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Age Group, 2020-2035

Table 5: Global Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 6: Global Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Region, 2020-2035

Table 7: North America Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Component, 2020-2035

Table 8: North America Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Device Type, 2020-2035

Table 9: North America Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Indication, 2020-2035

Table 10: North America Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Age Group, 2020-2035

Table 11: North America Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 12: North America Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Country, 2020-2035

Table 13: Europe Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Component, 2020-2035

Table 14: Europe Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Device Type, 2020-2035

Table 15: Europe Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Indication, 2020-2035

Table 16: Europe Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Age Group, 2020-2035

Table 17: Europe Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 18: Europe Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 19: Asia Pacific Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Component, 2020-2035

Table 20: Asia Pacific Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Device Type, 2020-2035

Table 21: Asia Pacific Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Indication, 2020-2035

Table 22: Asia Pacific Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Age Group, 2020-2035

Table 23: Asia Pacific Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 24: Asia Pacific Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 25: Latin America Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Component, 2020-2035

Table 26: Latin America Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Device Type, 2020-2035

Table 27: Latin America Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Indication, 2020-2035

Table 28: Latin America Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Age Group, 2020-2035

Table 29: Latin America Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 30: Latin America Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 31: Middle East & Africa Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Component, 2020-2035

Table 32: Middle East & Africa Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Device Type, 2020-2035

Table 33: Middle East & Africa Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Indication, 2020-2035

Table 34: Middle East & Africa Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Age Group, 2020-2035

Table 35: Middle East & Africa Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by End User, 2020-2035

Table 36: Middle East & Africa Wearable Continuous Glucose Monitoring Devices Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Frequently Asked Questions

;